Who makes GSK3915393 Solution for Infusion?

GSK3915393 Solution for Infusion is developed by GlaxoSmithKline.

What development phase is GSK3915393 Solution for Infusion in?

GSK3915393 Solution for Infusion is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GSK3915393 Solution for Infusion

GlaxoSmithKline · Phase 1 active Small molecule

At a glance

Generic name	GSK3915393 Solution for Infusion
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK3915393 Solution for Infusion CI brief — competitive landscape report
GSK3915393 Solution for Infusion updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI